Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans

Tapio Kerttula, Juha Alanko, Erkki Seppälä, Asko Riutta, I. Muchá, Eeva Sievi, Seppo Kaukinen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Amrinonea - phosphodiesterase III inhibitor - is used in the treatment of acute heart failure. In addition to its hemodynamic effects, amrinone has been shown to inhibit thromboxane synthesis in vitro. We investigated the effects of amrinone on thromboxane, prostaglandin, and leukotriene synthesis in humans. Eight healthy male volunteers took part in this single-blind study in which either amrinone (a 1.5-mg/kg bolus in 30 min and after that 10 μg/kg/min for 1 h 30 min) or placebo (0.9% NaCl) were infused. Amrinone infusion increased systolic blood pressure but had no significant effect on diastolic blood pressure or heart rate. Amrinone did not modulate thromboxane B2 synthesis stimulated by either spontaneous clotting or calcium-ionophore A23187 in whole blood. Amrinone had no effects on prostaglandin E2 or leukotriene E4 production in A23187-stimulated whole blood, nor did it affect urinary excretion of 11-dehydrothromboxane B2 or 2,3-dinor-6-keto- prostaglandin F(1α), the index metabolites of thromboxane A2 and prostacyclin productions, respectively. We conclude that amrinone has no effects on eicosanoid production in humans at the dose level used in this study, and that the hemodynamic effects noticed are not mediated via cyclooxygenase or lipoxygenase products of arachidonic acid metabolism.

Original languageEnglish
Pages (from-to)140-143
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 1999

Fingerprint

Amrinone
Type 3 Cyclic Nucleotide Phosphodiesterases
Phosphodiesterase Inhibitors
Arachidonic Acid
Blood Pressure
Thromboxanes
Calcimycin
Hemodynamics
Arachidonate Lipoxygenases
Leukotriene E4
Single-Blind Method
Thromboxane B2
Thromboxane A2
Eicosanoids
Calcium Ionophores
Leukotrienes
Prostaglandins F
Epoprostenol
Prostaglandin-Endoperoxide Synthases
Dinoprostone

Keywords

  • Amrinone
  • Leukotrienes
  • Phosphodiesterase
  • Prostacyclin
  • Prostaglan dins
  • Thromboxane

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans. / Kerttula, Tapio; Alanko, Juha; Seppälä, Erkki; Riutta, Asko; Muchá, I.; Sievi, Eeva; Kaukinen, Seppo.

In: Journal of Cardiovascular Pharmacology, Vol. 33, No. 1, 01.1999, p. 140-143.

Research output: Contribution to journalArticle

Kerttula, Tapio ; Alanko, Juha ; Seppälä, Erkki ; Riutta, Asko ; Muchá, I. ; Sievi, Eeva ; Kaukinen, Seppo. / Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans. In: Journal of Cardiovascular Pharmacology. 1999 ; Vol. 33, No. 1. pp. 140-143.
@article{ca6a73491bdb4ba9af04c83f92de8120,
title = "Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans",
abstract = "Amrinonea - phosphodiesterase III inhibitor - is used in the treatment of acute heart failure. In addition to its hemodynamic effects, amrinone has been shown to inhibit thromboxane synthesis in vitro. We investigated the effects of amrinone on thromboxane, prostaglandin, and leukotriene synthesis in humans. Eight healthy male volunteers took part in this single-blind study in which either amrinone (a 1.5-mg/kg bolus in 30 min and after that 10 μg/kg/min for 1 h 30 min) or placebo (0.9{\%} NaCl) were infused. Amrinone infusion increased systolic blood pressure but had no significant effect on diastolic blood pressure or heart rate. Amrinone did not modulate thromboxane B2 synthesis stimulated by either spontaneous clotting or calcium-ionophore A23187 in whole blood. Amrinone had no effects on prostaglandin E2 or leukotriene E4 production in A23187-stimulated whole blood, nor did it affect urinary excretion of 11-dehydrothromboxane B2 or 2,3-dinor-6-keto- prostaglandin F(1α), the index metabolites of thromboxane A2 and prostacyclin productions, respectively. We conclude that amrinone has no effects on eicosanoid production in humans at the dose level used in this study, and that the hemodynamic effects noticed are not mediated via cyclooxygenase or lipoxygenase products of arachidonic acid metabolism.",
keywords = "Amrinone, Leukotrienes, Phosphodiesterase, Prostacyclin, Prostaglan dins, Thromboxane",
author = "Tapio Kerttula and Juha Alanko and Erkki Sepp{\"a}l{\"a} and Asko Riutta and I. Much{\'a} and Eeva Sievi and Seppo Kaukinen",
year = "1999",
month = "1",
doi = "10.1097/00005344-199901000-00021",
language = "English",
volume = "33",
pages = "140--143",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans

AU - Kerttula, Tapio

AU - Alanko, Juha

AU - Seppälä, Erkki

AU - Riutta, Asko

AU - Muchá, I.

AU - Sievi, Eeva

AU - Kaukinen, Seppo

PY - 1999/1

Y1 - 1999/1

N2 - Amrinonea - phosphodiesterase III inhibitor - is used in the treatment of acute heart failure. In addition to its hemodynamic effects, amrinone has been shown to inhibit thromboxane synthesis in vitro. We investigated the effects of amrinone on thromboxane, prostaglandin, and leukotriene synthesis in humans. Eight healthy male volunteers took part in this single-blind study in which either amrinone (a 1.5-mg/kg bolus in 30 min and after that 10 μg/kg/min for 1 h 30 min) or placebo (0.9% NaCl) were infused. Amrinone infusion increased systolic blood pressure but had no significant effect on diastolic blood pressure or heart rate. Amrinone did not modulate thromboxane B2 synthesis stimulated by either spontaneous clotting or calcium-ionophore A23187 in whole blood. Amrinone had no effects on prostaglandin E2 or leukotriene E4 production in A23187-stimulated whole blood, nor did it affect urinary excretion of 11-dehydrothromboxane B2 or 2,3-dinor-6-keto- prostaglandin F(1α), the index metabolites of thromboxane A2 and prostacyclin productions, respectively. We conclude that amrinone has no effects on eicosanoid production in humans at the dose level used in this study, and that the hemodynamic effects noticed are not mediated via cyclooxygenase or lipoxygenase products of arachidonic acid metabolism.

AB - Amrinonea - phosphodiesterase III inhibitor - is used in the treatment of acute heart failure. In addition to its hemodynamic effects, amrinone has been shown to inhibit thromboxane synthesis in vitro. We investigated the effects of amrinone on thromboxane, prostaglandin, and leukotriene synthesis in humans. Eight healthy male volunteers took part in this single-blind study in which either amrinone (a 1.5-mg/kg bolus in 30 min and after that 10 μg/kg/min for 1 h 30 min) or placebo (0.9% NaCl) were infused. Amrinone infusion increased systolic blood pressure but had no significant effect on diastolic blood pressure or heart rate. Amrinone did not modulate thromboxane B2 synthesis stimulated by either spontaneous clotting or calcium-ionophore A23187 in whole blood. Amrinone had no effects on prostaglandin E2 or leukotriene E4 production in A23187-stimulated whole blood, nor did it affect urinary excretion of 11-dehydrothromboxane B2 or 2,3-dinor-6-keto- prostaglandin F(1α), the index metabolites of thromboxane A2 and prostacyclin productions, respectively. We conclude that amrinone has no effects on eicosanoid production in humans at the dose level used in this study, and that the hemodynamic effects noticed are not mediated via cyclooxygenase or lipoxygenase products of arachidonic acid metabolism.

KW - Amrinone

KW - Leukotrienes

KW - Phosphodiesterase

KW - Prostacyclin

KW - Prostaglan dins

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0032953036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032953036&partnerID=8YFLogxK

U2 - 10.1097/00005344-199901000-00021

DO - 10.1097/00005344-199901000-00021

M3 - Article

VL - 33

SP - 140

EP - 143

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -